35 research outputs found
Sedimentological control on carbonate cementation in the Luxembourg Sandstone Formation
The Luxembourg Sandstone Formation, i.e. a lower Jurassic offshore sandbar complex which was deposited in a general transgressive regime, was studied with the aim to unravel the controlling parameters and variations oil calcite cementation. This work was based on a combination of extensive fieldwork, petrographic and geochemical analyses. Cementation started with the development of acicular and equant cement. Both have been replaced in the meteoric realm by ferroan calcite cement. Elongated cemented lenses (10-100 m) are parallel to the bedding planes of cross-stratified layers. Coarse-grained cemented channels have a lensoid outline. Continuously cemented (>> 100 m) layers are present (1) as coarse-grained bioclastic rich layers in finer-grained lithologies (both sands and marls) and (2) at important lithological boundaries. Small nodules composed of sparitic to poikilotopic calcite cements, are aligned parallel to the stratification of the sandstones. The outline and distribution of the lenses is the result of an early cementation process, which affected carbonate-rich strata. Later diagenetic redistribution of unstable carbonate from the uncemented strata enhanced the early diagenetic signature. This resulted in zones containing a large amount of up to 100m elongated lenses, zones with smaller (1-10 m) lenses and zones without any lenses
Confirmation of a metastasis-specific microRNA signature in primary colon cancer
The identification of patients with high-risk stage II colon cancer who may benefit from adjuvant therapy may allow the clinical approach to be tailored for these patients based on an understanding of tumour biology. MicroRNAs have been proposed as markers of the prognosis or treatment response in colorectal cancer. Recently, a 2-microRNA signature (l et-7i and miR-10b) was proposed to identify colorectal cancer patients at risk of developing distant metastasis. We assessed the prognostic value of this signature and additional candidate microRNAs in an independent, clinically well-defined, prospectively collected cohort of primary colon cancer patients including stage I-II colon cancer without and stage III colon cancer with adjuvant treatment. The 2-microRNA signature specifically predicted hepatic recurrence in the stage I-II group, but not the overall ability to develop distant metastasis. The addition of miR-30b to the 2-microRNA signature allowed the prediction of both distant metastasis and hepatic recurrence in patients with stage I-II colon cancer who did not receive adjuvant chemotherapy. Available gene expression data allowed us to associate m iR-30b expression with axon guidance and l et-7i expression with cell adhesion, migration, and motility
Earliest Jurassic Patellogastropod, Vetigastropod, and Neritimorph Gastropods from Luxembourg with Considerations on the Triassic—Jurassic Faunal Turnover
New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)
High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients
Contains fulltext :
177761.pdf (publisher's version ) (Open Access)OBJECTIVE: Overall and splice specific expression of Spleen Tyrosine Kinase (SYK) has been posed as a marker predicting both poor and favorable outcome in various epithelial malignancies. However, its role in colorectal cancer is largely unknown. The aim of this study was to explore the prognostic role of SYK in three cohorts of colon cancer patients. METHODS: Total messenger RNA (mRNA) expression of SYK, SYK(T), and mRNA expression of its two splice variants SYK short (S) and SYK long (L) were measured using quantitative reverse transcriptase (RT-qPCR) in 240 primary colon cancer patients (n = 160 patients with chemonaive lymph node negative [LNN] and n = 80 patients with adjuvant treated lymph node positive [LNP] colon cancer) and related to microsatellite instability (MSI), known colorectal cancer mutations, and disease-free (DFS), hepatic metastasis-free (HFS) and overall survival (OS). Two independent cohorts of patients with respectively 48 and 118 chemonaive LNN colon cancer were used for validation. RESULTS: Expression of SYK and its splice variants was significantly lower in tumors with MSI, and in KRAS wild type, BRAF mutant and PTEN mutant tumors. In a multivariate Cox regression analysis, as a continuous variable, increasing SYK(S) mRNA expression was associated with worse HFS (Hazard Ratio[HR] = 1.83; 95% Confidence Interval[CI] = 1.08-3.12; p = 0.026) in the LNN group, indicating a prognostic role for SYK(S) mRNA in patients with chemonaive LNN colon cancer. However, only a non-significant trend between SYK(S) and HFS in one of the two validation cohorts was observed (HR = 4.68; 95%CI = 0.75-29.15; p = 0.098). CONCLUSION: In our cohort, we discovered SYK(S) as a significant prognostic marker for HFS for patients with untreated LNN colon cancer. This association could however not be confirmed in two independent smaller cohorts, suggesting that further extensive validation is needed to confirm the prognostic value of SYK(S) expression in chemonaive LNN colon cancer
New stratigraphic and geochemical data on the Holocene environment and climate from a tufa deposit at Direndall (Mamer Valley, Luxembourg)
International audienc
New stratigraphic and geochemical data on the Holocene environment and climate from a tufa deposit at Direndall (Mamer Valley, Luxembourg)
Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review
Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison
This study aimed to 'define responder' through the concept of minimum clinically important differences using the individually obtained standard errors (MCID-SE) and a heuristic 'external criterion' responsiveness method in patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). One hundred and fourteen newly diagnosed or relapsing patients (GBS: 55, CIDP: 59) were serially examined (1-year follow-up). The inflammatory Rasch-built overall disability scale (I-RODS), Rasch-transformed MRC sum score (RT-MRC), and Rasch-transformed modified-INCAT-sensory scale (RT-mISS) were assessed. Being-a-responder was defined as having a MCID-SE cut-off ≥1.96. Also, the correlations between patients' scores on each scale and the EuroQoL health-status 'thermometer' (external criterion) were determined (higher correlation indicated better responsiveness). In both diseases, the SEs showed a characteristic 'U'-shaped dynamic pattern across each scales' continuum. The number of patients showing a meaningful change were higher for the I-RODS > RT-MRC > RT-mISS and were in GBS higher than CIDP patients. The MCID-SE concept using Rasch-transformed data demonstrated an individual pattern of 'being-a-responder' in patients with immune-mediated neuropathies, and the findings were validated by the external criterion responsiveness method. The I-RODS showed greater responsiveness compared with the MRC and INCAT-sensory scales, and its use is therefore recommended in future trials in GBS and CIDP